Cemex SAB de CV

CX remains in a Stage 2 advance with confirmed higher highs and higher lows, supporting a bullish medium-term bias. However, price is range-bound near recent resistance and exhibiting signs of short-term exhaustion around the rising EMA band. We recommend stalking for pullbacks into the 9/21 EMA support area to participate in the continuation while avoiding late-stage extensions.

• ↑EBITDA rose 19% YoY to $1.2B driven by $90M Q3 cost savings.
• ↑Net sales hit $3.5B; volumes poised to grow 2.5–3%.
• ↓Negative earnings yield indicates valuation stretched relative to cash flow.